Enzaplatovir (BTA-585; BTA-C585) is a novel and orally bioavailable inhibitor of Respiratory Syncytial Virus (RSV) fusion protein with the potential for the treatment of respiratory syncytial virus infections.

纯度：≥98%

CAS：1323077-89-9